Latest news
FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease - NovartisNovartis · Sat, 08 Aug 2026 12:24:46 GMTPSMA PET Interpretation in Biochemical Recurrence After Prostate Cancer Treatment - Steve Cho - UroTodayUroToday · Fri, 07 Aug 2026 21:54:26 GMTTLX591 Antibody-Based Lutetium-177 PSMA Therapy in Metastatic CRPC - Pedro Barata - UroTodayUroToday · Thu, 06 Aug 2026 01:09:35 GMTFDA Approved Pluvicto Plus ARPI for PSMA-Positive mAPMN/S Prostate Cancer - OncodailyOncodaily · Wed, 05 Aug 2026 10:28:25 GMTWhy You Might Need a PSMA PET Scan for Advanced Prostate Cancer - Cleveland Clinic Health EssentialsCleveland Clinic Health Essentials · Tue, 04 Aug 2026 04:15:13 GMTFDA Approves Pluvicto for Early-Stage Metastatic Prostate Cancer - WebMDWebMD · Mon, 03 Aug 2026 23:11:02 GMTNovartis' Pluvicto leaps ahead into earlier manifestation of prostate cancer - Fierce PharmaFierce Pharma · Mon, 03 Aug 2026 12:33:04 GMTFDA Expands Approval of Pluvicto in Combination with ARPI for PSMA-Positive mAPMN/S Prostate Cancer - diagnosticimaging.comdiagnosticimaging.com · Sat, 01 Aug 2026 13:16:50 GMT